Characterization of Defects in Ion Transport and Tissue Development in Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)-Knockout Rats

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

Citation

Published Version
doi:10.1371/journal.pone.0091253

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:12064441

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Characterization of Defects in Ion Transport and Tissue Development in Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)-Knockout Rats

Katherine L. Tuggle1,2, Susan E. Birket1,3, Xiaoxia Cui5, Jeong Hong1,5, Joe Warren4, Lara Reid4, Andre Chambers4, Diana Ji4, Kevin Gamber4, Kenye K. Chu6,7, Guillermo Tearney6,8, Li Ping Tang1, James A. Fortenberry1,5, Ming Du1,9, Joan M. Cadilac9, David M. Bedwell1,10, Steven M. Rowe1,3, Eric J. Sorscher1,3, Michelle V. Fanucchi1,2*

1 Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham, Birmingham, Alabama, United States of America, 2 Department of Environmental Health Sciences, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, United States of America, 3 Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States of America, 4 SAGE Labs, Inc., St. Louis, Missouri, United States of America, 5 Department of Cell, Developmental, and Integrative Biology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America, 6 Wellman Center for Photomedicine, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, United States of America, 7 Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts, United States of America, 8 Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, United States of America, 9 Animal Resources Program, Office of the Vice President for Research, University of Alabama at Birmingham, Birmingham, Alabama, United States of America, 10 Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America

Abstract

Animal models for cystic fibrosis (CF) have contributed significantly to our understanding of disease pathogenesis. Here we describe development and characterization of the first cystic fibrosis rat, in which the cystic fibrosis transmembrane conductance regulator gene (CFTR) was knocked out using a pair of zinc finger endonucleases (ZFN). The disrupted Cfr gene carries a 16 base pair deletion in exon 3, resulting in loss of CFTR protein expression. Breeding of heterozygous (CFTR+/−) rats resulted in Mendelian distribution of wild-type, heterozygous, and homozygous (CFTR−/−) pups. Nasal potential difference and transepithelial short circuit current measurements established a robust CF bioelectric phenotype, similar in many respects to that seen in CF patients. Young CFTR−/− rats exhibited histological abnormalities in the ileum and increased intracellular mucus in the proximal nasal septa. By six weeks of age, CFTR−/− males lacked the vas deferens bilaterally. Airway surface liquid and periciliary liquid depth were reduced, and submucosal gland size was abnormal in CFTR−/− animals. Use of ZFN based gene disruption successfully generated a CF animal model that recapitulates many aspects of human disease, and may be useful for modeling other CF genotypes, including CFTR processing defects, premature truncation alleles, and channel gating abnormalities.


Editor: Prosper N. Boyaka, The Ohio State University, United States of America

Received September 20, 2013; Accepted February 10, 2014; Published March 7, 2014

Copyright: © 2014 Tuggle et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by CF Foundation Grant R464-CR07 (www.cff.org) and NIH P30 DK072482 (www.nih.gov) to EJS and R01 HL116213 to SMR. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have read the journal’s policy and have the following conflicts: XC, JW, LR, AC, DJ and KG are full-time employees of SAGE Labs, Inc., which sells genetically engineered rats and provides custom model creation services. KKC, EJS, SMR, and GT have filed a patent application related to use of µOCT technology in airways. The application serial number is PCT/US12/32553, entitled “Method for functional investigation of respiratory airways and other ciliated tissues using µOCT,” filed August 27, 2012. No financial benefit has yet been derived from this application by any author. SMR receives research support from the NIH, the Cystic Fibrosis Foundation (CFF), the American Lung Association, Synedgen Inc., and Forest Research Institute for basic and translational research. SMR also receives support from CFF Therapeutics (CFFT), Vertex Pharmaceuticals, PTC Therapeutics, N30 Therapeutics, and Novartis to conduct clinical trials related to the treatment and control of cystic fibrosis. SMR receives unrestricted research support for consulting services to Novartis, Kala Pharmaceuticals, Celsaas Inc., and Bayer Healthcare. SMR receives no personal income from any of the sponsors noted above. GT receives research support from lumien, Ninepoint Medical, Merck Research Laboratories, Canon, Samsung, and Air Liqide Medical Gases. GT. receives personal income from Ninepoint Medical, Terumo Corporation, and MIT through patent licensing arrangements. GT also receives consulting income from Samsung Advanced Institute of Technology and Ninepoint Medical. EJS receives research support from NIH, CFF, and CFFT. EJS serves as a scientific consultant to Genzyme, Pfizer, and Gilead. He receives consulting income from Gilead, KLT, SEB, JSH, LPT, JAF, MD, JMC, DMB, and MVF have no conflicts of interest to disclose. These disclosures do not alter the authors’ adherence to all PLOS ONE policies with regard to sharing data and materials.

Introduction

Cystic fibrosis (CF) is the most common lethal recessive genetic disorder among individuals of European descent, affecting 1 in every 2,500–3,500 newborns each year [1]. The disease is characterized by multi-system pathology, including respiratory complications, intestinal obstruction, exocrine pancreatic disease, hepatoductal blockage, and absence of the vas deferens [2]. The predominant cause of morbidity and mortality in CF results from chronic pulmonary infection and inflammation. CF is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, encoding an anion channel expressed in epithelial and other tissues.
A variety of CF mice have been generated since the discovery of Cb in 1989 [3,4]. The mouse models, while presenting with CF-related intestinal disease, fail to recapitulate many other manifestations observed in patients. Nonetheless, CF mice have provided a valuable tool for testing pharmaceutical and other interventions, and investigating contributors to pathogenesis, including CF modifier genes [5]. Porcine [6] and ferret [7] CF models exhibit a respiratory phenotype closely resembling that observed in humans, although prolonged gestational period, time to sexual maturation, expense, and specialized care requirements have significantly limited their widespread use.

The development of a CF rat (Rattus norvegicus) would provide a number of advantages in comparison with available animal models of CF. First, the rat has a very short gestational period (21–23 days) and time to sexual maturity (5 weeks), allowing rapid colony propagation, breeding studies, and characterization of animals as they mature shortly after birth. Second, there is considerable interest regarding airway glandular function as a mediator of CF respiratory failure [8]. Airway submucosal glands are believed to underlie considerable pathology observed in human CF lungs. Rats are an attractive model in this context because, unlike mice but similar to humans, rats develop extensive submucosal glands throughout the trachea to the level of bronchi [9]. Third, relative to mice, rats are considerably larger in size, even during the early postnatal period, allowing for larger tissue samples to be collected from animals and ease performing surgical procedures [10]. Rats are also a traditional species for pharmacology and toxicology research due to their well-defined pharmacokinetic and biodistribution profiles [11,12]. Previous CF studies have sometimes required transgenic mice for efficacy, with safety studies conducted in rat; however, a CF rat model would facilitate pharmaceutical efficacy and safety studies of potential therapeutic molecules in the same species. Finally, because rats have been well studied in the laboratory for years, there is a large body of literature regarding normal physiology and a vast array of laboratory tools and reagents (i.e. antibodies, siRNA, other genomic probes) readily available for the study of chaperone, binding partner, and other protein based analyses relevant to disease mechanism that would be very difficult to obtain for ferret or pig.

Recent advances in gene manipulation techniques have provided a number of opportunities for developing genetically modified animals other than mouse. Zinc-finger endonuclease (ZFN) technology, for example, allows targeting of user-defined site-specific mutations that generate knockout animals with high efficiency and over a shorter time line than embryonic stem-cell propagation, breeding studies, and characterization of animals as they mature shortly after birth. Here, we describe the generation of a CFTR−/− rat by pronuclear microinjection of ZFNs and its characterization. The disease phenotypes observed in young (21–44 days postnatal) CFTR−/− animals, which closely resemble human manifestations, suggest the rat model will be useful for studies of CF pulmonary pathogenesis and drug development.

Materials and Methods

Ethics Statement
This study was carried out in compliance with the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. Protocols were approved by the SAGE Labs, Inc. or University of Alabama at Birmingham (UAB) Institutional Animal Care and Use Committee (IACUC; SAGE Approval Number 001.02, UAB Approval Number 09479). All surgeries were performed under sodium pentobarbital or ketamine/xylazine/acepromazine anesthesia with all efforts made to minimize animal suffering.

Generation of the Model

ZFN mRNA preparation. Cb specific ZFNs were obtained from the CompoZr product line (Sigma, St. Louis, MO). mRNA was prepared from each construct, linearized with Xhol and modified using MessageMax and Poly(A) polymerase tailing kits (Epicentre Biotechnology). Samples were purified, quantified, and transfected at a 1:1 ratio into rat C6 cells for activity validation.

Animal husbandry. Derivation and breeding of animals was conducted at SAGE Labs (microinjection and founder identification/breeding) operated under approved animal protocols overseen by the SAGE IACUC. Sprague Dawley rats (N:ac:SD) from Taconic Farms (Hudson, New York) were used for microinjection. Animals were bred with housing in standard cages maintained on a 12 h light/dark cycle with ad libitum access to food and water. Routine health monitoring of the colony was performed at IDEXX (Columbia, MO) and indicated no evidence of infection with known serious pathogens.

Microinjection. Four to five week-old female donors were injected with 20 units of pregnant mare serum gonadotropin (PMS) followed by injection of 50 units hCG after an additional 48 h, and immediately mated with stud males. Fertilized eggs were harvested a day later. Cb ZFN mRNA was microinjected at 10 ng/ml into the pronucleus of fertilized eggs. Following microinjection, 25–30 eggs were transferred into each pseudo-pregnant female, leading to birth of the founder generation.

Founder identification and breeding. Tail or toe biopsies were used for genomic DNA extraction and analysis as described previously [15]. Primers flanking the target site were forward 5′-AATATCTGTTGGGCGATTTG and reverse 5′-TTGTGTTGCCAGATTGCCCTT. Primers used to detect larger insertions were forward 5′-AATATCTGTTGGGCGATTTG and reverse 5′-GAGGATGTTGGGAAGCTTTG. A founder was selected and bred with wild-type to obtain heterozygous animals, and sibling mating of heterozygotes resulted in homozygous SD-CFTR−/− rats (termed CFTR−/−).

Characterization of the Model

Animals. All animal experiments at UAB were conducted in accordance with UAB IACUC approved protocols. Male and female Sprague-Dawley CFTR−/− rats were paired and housed in HEPA filtered ventilated cages with a 12 hour light/dark cycle and provided sterilized food and water ad libitum. Litters remained with lactating dams until weaning. Heterozygous rats were separated from wild-type and CFTR−/− littersmate. Heterozygous animals exhibited growth and survival rates similar to wild-type, did not develop intestinal obstruction, and presented with normal dentition and complete male reproductive organs. In preliminary studies, CFTR heterozygotes also exhibited similar bioelectric and other characteristics to wild-type. In order to preclude any subtle confounding variables, CFTR+/− carriers were excluded from data analysis shown in this manuscript. Wild-type and CFTR−/− animals were provided water and standard rodent chow (pellet and ground) with a supplemental diet of DietGel 76A (Clear H2O). A subset of wild-type and CFTR−/− pups were also provided 1× GoLytely (Braintree Laboratories, Inc) at weaning as a means to reduce gastrointestinal complications.

PCR genotyping. DNA analysis of litters was performed by extracting tail snap genomic DNA prepared in 500 μl lysis buffer (200 mM NaCl, 100 mM Tris-HCl, 5 mM EDTA, 0.25% Tween-20) with 1 mg Proteinase K (Sigma P6556) overnight at room temperature, followed by 60°C incubation to complete tissue
lization. DNA was obtained by standard techniques with 2-propanol, 70% ethanol, and DNA stored TE buffer (10 mM Tris-HCl, 1 mM EDTA) at −20 °C. For PCR, 1 μL of DNA was mixed with 8 μL H2O, 10 μL JumpStart Taq ReadyMix (Sigma P2893), and 0.5 μL each primer (forward 5'-GACGCTCATGGTGCTGATC-3', reverse 5'-GACCATXTATTTGCAAGGGAGAG-3').

PCR conditions were 95 °C for 5 minutes, followed by 35 cycles of 95 °C for 30 seconds, 60 °C for 30 seconds, and 72 °C for 40 seconds, with a fixed cycle at 68 °C for 5 minutes. This PCR resulted in amplification of a 172-bp DNA fragment for the wild-type Cftr allele and a 168-bp DNA fragment (16-bp deleted) for mutant Cftr. PCR products were resolved on a 3.5% agarose gel.

Western blotting. Lung tissue was homogenized in TBS on ice followed by lysis in RIPA buffer (ThermoScientific, Rockford, IL) with Halt protease inhibitor cocktail (ThermoScientific). Protein was quantitated using the BCA assay (ThermoScientific), samples mixed with 4× sample buffer, and incubated at 37 °C for 10 minutes. Equal amounts of protein (20 μg) were loaded into each lane, resolved by SDS-PAGE, and blotted onto PVDF membranes. Wild-type Sprague-Dawley rat lung extract (Sc-2396, Santa Cruz Biotechnology, Inc, Dallas, Tx) was used as an additional positive control for CFTR detection. Blocking was with 1% rabbit serum followed by incubation with goat anti-CFTR primary antibody (1:200 Sc-8909) overnight at 4 °C, and subsequent rabbit anti-goat HRP conjugated secondary antibody (1:5000 Sc-2768) for 1 hour at room temperature. Labeled proteins were detected using SuperSignal West Femto ECL kit (ThermoScientific).

Histology. Left lung lobes were cannulated and inflation fixed with 1% paraformaldehyde at 30 cm pressure for 30–60 minutes, followed by storage in 10% buffered formalin. Nasal tissue was collected, mandible removed, and nasal passages flushed retrograde with 10% buffered formalin followed by immersion in formalin until processed [16]. Nasal samples were decalcified for 4–5 days in Immunocal (Decal Chemical Corporation, Tallman, NY) solution, and rinsed thoroughly. The nasal cavity was sectioned into four regions at specific anatomic sites as described previously [17,18]. All other tissues were harvested, immersion fixed in 10% buffered formalin or 70% ethanol/formalin and stored at 4 °C until processed. Tissues were embedded in paraffin, sectioned, and stained with hematoxylin and eosin (H&E) for evaluation by a board certified veterinary pathologist. Nasal, tracheal, lung, and intestinal tissues were stained with alcian blue periodic acid Schiff (AB-PAS) for identification of mucosubstances. Sections were imaged on an Olympus BX-41 microscope with a digital Q-color 5 camera (Olympus) using Q Capture imaging software (Q Imaging, Surrey, Canada) [19].

Quantitation of intracellular mucus in the nasal septa. The amount of stored mucosubstance in upper respiratory epithelium was estimated by quantifying the area of AB-PAS positive tissue per unit basement membrane. Septa from proximal nasal samples were evaluated at 20×, providing 4–6 fields (entire length of septa) per animal. Images were imported into ImageJ (NIH) and colors separated using the RGB stack feature. Using a green channel, areas of interest were outlined using the polygon tool and maximum threshold set for each image to include all stained intracellular mucus.

Morphometric analysis of tracheal tissue. Tracheas were imaged at 4× and 20× magnification followed by analysis with ImageJ (NIH) using protocols modified from Meyerholz et al. [20]. For each animal, three tracheal sections were studied (with a minimum distance of 15 μm between sections) using the following parameters. Lumenal circumference was determined by measuring the apical surface of the epithelium. Cartilage area was quantified by outlining cartilaginous tissue in the tracheal ring, measuring the area, and summing area for all cartilage in each image. Maximal cartilage thickness was evaluated by determining the perpendicular distance between outer boundaries of cartilage rings, with epithelial thickness represented by the distance between the basement membrane (on the serosal surface) and the apical membrane lumennally. Submucosal gland area was determined by circling and measuring both serous and mucus components of the gland structures. Submucosal gland intracellular mucus was assessed by outlining the entire submucosal gland area (same protocol as for quantitation of intracellular mucus in the nasal septa), in order to define the extent of intracellular mucosubstance. The percent of intracellular mucus was determined as the ratio of intracellular mucus/total submucosal gland area.

Bioelectric Measurements
Nasal potential difference. Rats were anesthetized with ketamine (200 mg/kg), acepromazine (0.6 mg/kg), and xylazine (30 mg/kg) by intraperitoneal injection. Potential difference was measured using AgCl electrode and electronic data capture (AD Instruments) as previously described for mouse and human [21,22]. Nasal cavities were perfused sequentially with 1) Ringer solution containing 140 mM NaCl, 5 mM KCl, 1 mM MgCl2, 2 mM CaCl2, 10 mM HEPES, and 100 μM amiloride (pH 7.3); 2) Cl free Ringer solution (6 mM Cl−, pH 7.3) with amiloride; and 3) Cl free Ringer solution, amiloride, and forskolin (20 μM). Each condition was studied for 5 to 10 minutes until a stable signal was achieved. Traces were interpreted in a blinded fashion.

Tracheal short-circuit current (ISc). Tracheas were excised, sectioned into 3–4 segments, and opened longitudinally along the dorsal surface. Segments were mounted as flat sheets in modified Ussing chambers (area ~0.031 cm2) maintained at 37 °C and bubbled vigorously with 95% O2:5% CO2.

ISc measurements were performed under voltage clamp conditions using MC8 equipment and P2300 Ussing chambers (Physiologic Instruments, San Diego, CA). Tissue segments were equilibrated for 10 minutes in regular Ringer solution that contained (in mM) 120 NaCl, 25 NaHCO3, 3.33 KH2PO4, 0.83 K2HPO4, 1.2 CaCl2, 1.2 MgCl2, and 10 mannitol to establish a baseline and then tested by one of the following experimental protocols:

1. Administration of amiloride (100 μM) to inhibit the epithelial sodium channel (ENaC), followed by sequential addition of forskolin (10 μM) to activate cAMP-dependent CFTR current, ATP (10 μM) to activate Ca2+-activated chloride channel (CaCC) transport, and bumetanide (100 μM) to block transepithelial Cl− transport.

2. Administration of CFTRinh-172 (10 μM) to block constitutively active CFTR dependent chloride current, followed by sequential addition of amiloride, ATP, and bumetanide as above.

Changes in ISc; attributable to ion transport agonists and inhibitors were calculated following achievement of a stable plateau for several minutes. ATP-sensitive ISc was measured as the highest current value for each sample [21].

Ileal ISc measurements. Tissue segments approximately 8 mm in length sectioned 5 cm above the cecum were stripped of the serosa (visceral peritoneum) and longitudinal/circular muscle layers of the intestinal wall, opened longitudinally along the mesenteric border, and incubated in TTX (Tetrodotoxin, 3.3×10−4 μM in PBS) for 10 min to block action potential dependent sodium channels. Segments were mounted as flat sheets.
onto sliders (area ~0.09 cm²) and Isc measured under voltage clamp conditions using MC8 equipment and P2300 Using chambers (Physiologic Instruments, San Diego, CA) as previously described [23]. Bath solutions were gently stirred and gassed with 95% O₂:5% CO₂.

Regular Ringer solution was utilized for monitoring Isc as above. Low Cl⁺ Ringer contained (in mM) 1.2 NaCl, 25 NaHCO₃, 3.33 KH₂PO₄, 0.83 K₂HPO₄, 1.2 CaCl₂, 1.2 MgCl₂, 141 Na gluconate, and 10.8 mannitol. Sliders with mounted ileum were equilibrated for 10 minutes in Ringer solution followed by 10 minutes of recording; mucosal side chambers were changed to 1:1 regular Ringer:low Cl⁺ Ringer. Indomethacin (10 μM) was added to both chambers to block ion transport associated with mIsobutyl-1-methylxanthine, 100 (Pathology Devices, Westminster, MD). Tracheas were equilibrated for 10 minutes of recording; mucosal side chambers were changed to 1:1 regular Ringer:low Cl⁺ Ringer. Indomethacin (10 μM) was added to both chambers to block ion transport associated with phospholipase C or A2 activity induced by seromuscular stripping. After 30 minutes of incubation, forskolin (10 μM) and IBMX (3-Isobutyl-1-methylxanthine, 100 μM) were added to both chambers, followed by glybenclamide (200 μM) to block forskolin-activated CFTR short-circuit current.

In all experiments, fully stimulated current was obtained within 3 minutes of forskolin addition. Pulse during voltage clamp measurements was imposed every second after forskolin/IBMX stimulation, and every 20 seconds following other drug treatments.

Micro Optical Coherence Tomography (μOCT)

Tissue preparation. Tracheal tissue was excised, immediately placed on Gelfoam soaked in DMEM/F12 1: 1 media, and incubated under physiologic conditions (37°C, 5% CO₂, and 100% humidity) using an environmentally controlled chamber (Pathology Devices, Westminster, MD). Tracheas were equilibrated for 30 minutes before analysis.

Image acquisition. Measurements of functional microanatomic parameters in tracheal tissue, including measurement of (i) airway surface liquid (ASL) depth; the aqueous layer lining the airway epithelium, (ii) periciliary liquid (PCL) depth, the thin aqueous gel surrounding the cilia, (iii) ciliary beat frequency (CBF), and (iv) velocity of mucociliary transport (MCT) were performed using Micro-Optical Coherence Tomography (μOCT), a high-speed, high-resolution microscopic reflectance imaging modality [24]. μOCT methods for investigation of airway epithelium and quantitative image analysis have been previously described [24,25]. In brief, the μOCT instrument provides cross-sectional images of epithelium with a transverse and axial resolutions of approximately 2 μm and 1 μm, respectively. This resolution is sufficient to directly visualize and quantify parameters including ASL depth, PCL depth, CBF, and MCT rate without using exogenous dyes or particles. Acquisition speed is 20,480 Hz line rate, resulting in 40 frames per second at 512 lines per frame.

Image analysis. Quantitative analysis of ASL and PCL depths were characterized directly by geometric measurement of the respective layers, and images over several frames captured the length of fully extended cilia. CBF was investigated by Fourier analysis of the reflectance due to beating cilia. MCT rate was determined using time elapsed and distance traveled of native particulates in the mucus over multiple frames. Images were acquired at randomly chosen locations on the mucosal surface with the optical beam scanned along the longitudinal axis of the trachea.

Bronchoalveolar lavage fluid cell differentials. Tracheas were cannulated and lungs lavaged with 2.0 mL PBS (7.4 pH). Cells were collected by instilling 2.0 mL phosphate buffered saline (pH 7.2) and the lavage centrifuged onto slides (Cytospin). Slides were stained using Hema 3 stain kit (Fisher Scientific, Kalamazoo, MI) [26]. A minimum of 300 cells were counted per animal.

Complete Blood Counts (CBC) and serum chemistry. Blood (200–500 μL) was collected from the brachial artery into EDTA tubes and processed for CBC by ANATECH Diagnostics (Smyrna, GA). For serum chemistry, whole blood (300–500 μL) was processed in serum separator tubes and allowed to clot at room temperature for 1 hour. Supernatant was obtained by centrifugation at 10,000 g for 10 minutes, with serum placed in a fresh tube and frozen at −80°C. Samples were thawed and analyzed on an Abaxis VetScan using a Comprehensive Diagnostic Profile rotor (500–1038, Union City, CA).

Statistical analysis. Data are expressed as mean ± SEM or as individual data points. Statistical significance was determined using unpaired, two-tailed Student’s t-test or one-way ANOVA using Prism (GraphPad, LaJolla, CA). For survival analysis, Kaplan-Meier survival curves were plotted and statistical significance determined using the logrank test for trend. P values ≤0.05 were considered significant.

Results

Microinjection and Founder Identification

A pair of ZFNs was confirmed to cleave the target site within exon 3 of Cftr, shown in Figure 1A. Following microinjection and embryo transfer, 44 pups were born to six recipients, 18 of which carried at least one mutant allele. The mutations ranged from 9 bp to hundreds of base pairs in length. Seven founders carried the same 9 bp deletion (Figure 1B), presumably due to microhomology within the target site, as discussed previously [15]. One founder was mosaic, harboring wild type Cftr allele, an allele with a 16 bp deletion and an allele with a 479 bp deletion. Larger deletions were observed to span the junction of exon 3/intron 3. Heterozygous rats with the 16 bp deletion (a frameshift in the reading frame leading to premature termination in exon 4) (Figure 1C), were used to establish a breeding colony.

Litter Demographics

Four breeding pairs of CFTR⁺/− rats gave rise to 332 pups from 30 litters with an average litter size of 11 pups. Litters were analyzed by PCR (Figure 2B) and found to have a genotype distribution of 27.1% wild-type, 49.4% heterozygous, and 23.5% CFTR⁻/−, a result similar to the expected 1:2:1 inheritance pattern. Western blot of whole lung homogenates from wild-type and CFTR⁻/− animals confirmed that the 16 bp deletion resulted

Figure 1. Targeting in exon 3 of Cftr. (A) ZFN recognition site sequence. The two ZFN binding sites are in bold uppercase. Cleavage site is in lower case. (B) Nine base pair deletion recovered in multiple founders. The deleted sequence is shown in gray. Microhomology that may have favored this deletion is marked in boxes. (C) Schematic of the gene structure of the first 5 exons of rat Cftr. Exons are shown by filled rectangles with exon number above. ATG, position of the translational start codon; Δ16 bp marks the position of 16 bp deletion, with nucleotide sequence below. *indicates premature stop mutations introduced by the 16 bp deletion in exon 3. doi:10.1371/journal.pone.0091253.g001
in loss of CFTR protein expression (Figure 2C and Figure S3). At birth, body weight and overall body size were similar between wild-type and CFTR $^{-/-}$ animals; however, beginning in the second week following birth, CFTR $^{-/-}$ rats gained weight more slowly than wild-type littermates (Figure 2A, 2D). Survival of CFTR $^{-/-}$ rats was similar to wild-type until weaning, but was greatly reduced by 6 weeks (30% vs 99%, p ≤ 0.05; Figure 2E). Mortality was associated with weight loss secondary to gastrointestinal complications (including obstruction, see also below).

Addition of GoLytely to water resulted in significantly improved survival rates of CFTR $^{-/-}$ animals at 6 weeks of age (30% vs 64%, p ≤ 0.05; Figure 2E).

Illeal Tissue

CFTR $^{-/-}$ rats developed intestinal obstruction after weaning and exhibited significant weight loss and decreased survival. Histological evaluation of small intestine demonstrated epithelial cell sloughing and crypts dilated with mucus, as well as a qualitative increase in bacterial load (Figure 3A). Ileal tissue was evaluated for CFTR short-circuit current phenotype by Ussing chamber measurements. Wild-type ileal tissue exhibited a strong forskolin-stimulated current (150±49 μA/cm²), which was absent in CF rats (9±6 μA/cm², p≤0.0001; Figures 3B, C).

Stored Mucosubstances in Airway Epithelium of the Proximal Septa

The respiratory epithelium of the nasal septum, immediately posterior to the upper incisors, was evaluated and labeled for intracellularly stored mucosubstance. Both wild-type and CFTR $^{-/-}$ animals had normally developed epithelium consisting of a pseudostratified columnar epithelium comprised of both goblet and ciliated epithelial cells. CFTR $^{-/-}$ animals had elevated levels of intracellular mucus that encompassed a significant portion of the airway epithelial cytosol (Figure 4A, Table 1), resulting in cells from CF animals appearing thicker and swollen (“stuffed”) compared to wild-type.

Nasal Potential Difference Measurements

To characterize electrophysiology of the upper airway, trans-epithelial potential difference was monitored in response to a series of pharmacologic ion channel regulators. CFTR $^{-/-}$ rats had no evidence of Cl$^-$ dependent secretion upon stimulation of CFTR mediated Cl$^-$ transport by Cl free Ringer with forskolin (3.8±0.6 mV), whereas changes were robust in wild-type littermates (~9.3±2.7 mV, p≤0.01; Figure 4B, C). There were no differences between CF and non-CF following perfusion with amiloride. These measurements indicate a bioelectric phenotype consistent with absence of CFTR in the nasal airways, but without concomitant increase in amiloride sensitive voltage, the conventional ion transport pathway associated with sodium reabsorption.

Morphometric Analysis of Tracheal Rings

Tracheal morphology in young CF animals appeared grossly similar between wild-type and CFTR $^{-/-}$ genotypes (Figure 5); however, morphometric analysis revealed important differences attributable to absent CFTR (Table 1). While luminal circumference was not significantly different between wild-type and CFTR $^{-/-}$ rats at 3–6 weeks after birth, cartilage area was significantly diminished in CF animals. CF rats also exhibited reduced tracheal gland area (~50% compared to wild-type) even after normalization for tracheal lumen circumference. Additionally, at all time points during the 3–6 week growth period, alcian blue positive (AB+) staining of submucosal glandular cells was decreased in CF versus wild-type rats, suggesting that glandular maturation in the CF animals was delayed in comparison to age-matched controls.

Tracheal ISC Measurements

Baseline ISC of freshly excised trachea was significantly lower in CFTR $^{-/-}$ animals compared to wild-type (Figure 5B), a finding predominantly attributable to CFTRinh-172 sensitive current. To determine the contribution of Na$^+$ transport to basal currents,
Figure 3. Histology and short-circuit current measurements from small intestines of wild-type and CFTR−/− rats. H&E (bar = 200 μm) and AB-PAS (bar = 100 μm) stained sections of the small intestines from wild-type and CFTR−/− rats. (n = 3–5 animals/group) (B) ISc tracings from wild-type and CFTR−/− rat ileum. (C) Summary of forskolin stimulated current measurements from ileal sections. (n = 5 animals/group) ****p≤0.0001. doi:10.1371/journal.pone.0091253.g003
Figure 4. Proximal nasal histology and nasal potential difference measurements. (A) Low power magnification (4×) H&E stained sections from the proximal nasal passages bar = 500 μm. 20× images of ABPAS stained nasal septa from boxed areas bar = 25 μm. Arrowheads, cells swollen with intracellular mucus; e, respiratory epithelium; g, submucosal gland; dashed line (–), basement membrane (n = 4 animals/group) (B) NPD tracings from wild-type and CFTR−/− rats. (C) Summary data from NPD measurements for Δamiloride, ΔCl−-free Ringers, Δforskolin, and ΔCl−/− free Ringers+ forskolin. (n = 5 animals/group) **p<0.01.
doi:10.1371/journal.pone.0091253.g004
amiloride was added apically (Figure 5B, left panel). The reduction in ISc was similar for both wild-type and CFTR−/− rats (49 ± 11 μA/cm² and 64 ± 21 μA/cm², respectively; Figure 5C) indicating comparable levels of sodium transport irrespective of CFTR expression (Figure 5B, left panel; a finding similar to the nasal ion transport phenotype, Figure 4). Subsequent addition of forskolin did not confer substantial ISc activation in either group, suggesting CFTR may be constitutively active in wild-type sections, diminishing the additional activation otherwise expected from forskolin. In contrast, ATP stimulated current was much greater for CFTR−/− animals (although maximal Cl− currents for both genotypes were comparable and inhibited by addition of bumetanide), suggesting a compensatory increase of ATP-dependent Cl− transport in the absence of functional CFTR, as also seen in humans [27]. To confirm that CFTR was constitutively active in wild-type animals, an alternative protocol was developed to test this interpretation (Figure 5B, right panel). Using the modified assay, wild-type rats demonstrated a baseline current of 547 ± 102 μA, while current was far less (61 ± 17 μA) in CFTR−/− animals. Addition of CFTRinh-172 reduced the current in wild-type by 30%, yet CFTR−/− rats maintained normally filed teeth while CF animals exhibited grossly malformed dentition, possibly due to defective physiological trimming. Without intervention, incisors of CF rats developed dental malformations, including curvature of the incisors and penetration of the hard palate (Figure 8B).

Lung and Major Exocrine Tissues from CFTR−/− Rats are without Pathology or Inflammatory Cell Infiltrates During Early Life

Pulmonary sections from wild-type and CFTR−/− rats appear to develop normally from days 22 to 42 (Figure 8A). Wild-type rats maintained normally filed teeth while CF animals exhibited grossly malformed dentition, possibly due to defective physiological trimming. Without intervention, incisors of CF rats developed dental malformations, including curvature of the incisors and penetration of the hard palate (Figure 8B).

Hematology and Serum Chemistry

Hypoalbuminemia, decreased total protein, and increased blood urea nitrogen (Table S1) were observed in CFTR−/− rats. Because many animals experienced substantial weight loss prior to euthanasia, these findings may be attributable in part to malnourishment and poor hydration. Serum electrolytes (Ca²⁺, Na⁺, K⁺) were not different between wild-type and CFTR−/− groups (Table S1). A trend towards increased blood glucose levels was observed in CF animals with very high values in a subset (data not shown) which is currently under investigation.

Red blood cells, hemoglobin, and hematocrit were all within normal range for young animals. Total white blood cell counts were not different between groups, although the differential was influenced by genotype (Wild-type: 21 ± 4% neutrophils and 76 ± 4% circulating lymphocytes, CFTR−/− animals: 52 ± 5% neutrophils and 44 ± 6% circulating lymphocytes), likely attributable to gastrointestinal or other stress-related complications observed in CFTR−/− animals.

**Table 1.** Morphometric analysis of respiratory tissue from 3–6 week old wild-type and CFTR−/− rats.

<table>
<thead>
<tr>
<th></th>
<th>Wild-type</th>
<th>CFTR−/−</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Nasal Septa</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intracellular mucus/basement membrane (μm²/μm)</td>
<td>3.5±0.9</td>
<td>7.5±0.9*</td>
</tr>
<tr>
<td><strong>Trachea</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lumen circumference (mm)</td>
<td>5.5±0.3</td>
<td>5.1±0.2</td>
</tr>
<tr>
<td>Cartilage area (mm²/m²)</td>
<td>0.63±0.06</td>
<td>0.42±0.03**</td>
</tr>
<tr>
<td>Cartilage area/lumenal circumference (mm²/mm)</td>
<td>0.11±0.01</td>
<td>0.08±0.01*</td>
</tr>
<tr>
<td>Maximum cartilage thickness (mm)</td>
<td>0.20±0.01</td>
<td>0.17±0.01</td>
</tr>
<tr>
<td>Epithelial thickness (μm)</td>
<td>11.5±0.7</td>
<td>9.9±1.09</td>
</tr>
<tr>
<td>Submucosal gland area (mm²)</td>
<td>0.057±0.005*</td>
<td>0.032±0.006*</td>
</tr>
<tr>
<td>Submucosal gland area/lumenal circumference (mm²/mm)</td>
<td>0.016±0.001</td>
<td>0.006±0.001*</td>
</tr>
<tr>
<td>Submucosal gland intracellular mucus (μm²)</td>
<td>7409±1481</td>
<td>2877±752*</td>
</tr>
<tr>
<td>% intracellular mucus</td>
<td>12±2</td>
<td>8.4±2</td>
</tr>
</tbody>
</table>

Values shown as mean ± SEM (n=4–6 animals/group). *p<0.05, **p<0.001 (Student’s t-test).

doi:10.1371/journal.pone.0091253.t001
Figure 5. Tracheal histology and short circuit current measurements. (A) AB-PAS stained tracheal sections from 6 week old rats. Submucosal glandular tissue indicated by arrowheads. Low magnification bar = 500 μm, high magnification bar = 50 μm (B & C) Summary data from Ussing chamber short circuit current measurements. Panels on right depict a modified protocol designed to specifically detect baseline (constitutive) CFTR function. (n = 3–6 animals/group) **p<0.01, ***p<0.001, ****p<0.0001. doi:10.1371/journal.pone.0091253.g005
Figure 6. Functional anatomy of rat trachea. (A) Representative time-averaged μOCT images of wild-type and CFTR<sup>−/−</sup> tracheas. Higher magnification insets (bottom left corner) show differences in ASL height between wild-type and CFTR<sup>−/−</sup> animals. White magnification bar = 10 μm. Red bars indicate ASL height. Mucus layer (mu), epithelium (ep), lamina propria (lp), and gland duct (gd) are also visualized. (B) Summary data for airway surface liquid depth (ASL), periciliary liquid depth (PCL), ciliary beat frequency (CBF), and mucociliary transport (MCT). (n = 8–13 animals/group) *p ≤ 0.05.

doi:10.1371/journal.pone.0091253.g006
Discussion

We present here a novel cystic fibrosis rat with a number of phenotypic characteristics that resemble the human disease. The CF rat furnishes a new opportunity to investigate (i) developmental processes that affect disease progression and severity, (ii) the impact of CFTR and other ion channels with regard to ASL depth in CF airways, (iii) contributions of ASL and PCL abnormalities to manifestations of CF respiratory pathology, and (iv) the role of CFTR in mucus synthesis and release.

Developmental defects attributable to absent CFTR have received considerable recent attention, including abnormal airway remodeling and tracheal formation [20], deficient levels of growth hormone [28], absent vas deferens [7,29], and problems with enamel deposition in teeth [30–33]. Similar to CF pig [20] and human subjects [20,34], we observed reduced tracheal circumference and a loss of submucosal gland area in the CF rat model (Figure 2), supporting the notion that CFTR may play a critical role during normal lung development [20]. The CF rat offers an ideal opportunity to monitor phenotypes such as these more longitudinally than has been practical in the past (e.g. from intrauterine tissue formation to adulthood).

The rat model will also serve as a valuable resource for investigating developmental events that lead to abnormalities of the male reproductive tract. The majority (>99%) of men with CF are sterile due to degeneration or complete absence of the vas deferens [35]. In both the CF pig and ferret, the vas deferens is poorly formed or absent at birth [7,29]. The most commonly utilized CF animal model, the mouse, does not exhibit this feature. CF rats have lost the vas deferens by 6 weeks of age. The role of chloride secretion versus intracellular or other CFTR functions with regard to vas deferens involution are not well understood, but can be more readily characterized in vitro and in vivo using this new animal model. The rat may also facilitate experiments intended to determine the extent to which vas tissue destruction can be ameliorated by early (e.g. prenatal) therapeutic intervention.

Another area of increasing interest is the development of dental complications in CF subjects. Similar to observations in mice [33], CFTR<sup>−/−</sup> rats exhibit white incisors compared to yellow dentition of wild-type littermates (Figure 8A). Moreover, by three months of age CF rats demonstrate grossly malformed upper and lower incisors, characterized by curved dentition and penetration of the hard palate (Figure 8B). Additional studies are in progress to determine whether this phenotype is the result of (i) dysregulated growth and/or (ii) reduced wearing of the teeth, and the extent to which hypomineralization or other defects in enamel contribute to the findings [30,31,33,36]. Human data indicate that many CF patients have diminished mineralization of enamel [37–40] which may predispose to development of caries. The rat represents an ideal means of further investigating this feature of clinical CF.

The relationship of ASL depth to pathogenesis of cystic fibrosis lung disease has engendered considerable controversy. Previous studies have concluded that depleted ASL is primarily responsible for cystic fibrosis pulmonary damage, and associated with defects in ciliary extension [41]. The present results in CFTR<sup>−/−</sup> animals indicate ASL depletion in lower airways (Figure 6) that is qualitatively and quantitatively very similar to that noted in human subjects [42], but without evidence of overt respiratory pathology (Figure S1). Our findings establish that defective ASL hydration can occur for several weeks without resulting in manifestations of a CF pulmonary phenotype. While spontaneous lung disease is absent in very young CF rats, it is important to note that the animals described here have been housed in HEPA
filtered ventilated cages. Future studies will determine whether older animals maintained under more natural housing conditions develop evidence of lower respiratory involvement. If such experiments fail to elicit a CF phenotype, the findings would indicate that defects in ASL and PCL hydration by themselves do not represent a proximate cause of CF pathology. The rat model will therefore furnish a valuable means to address unanswered questions regarding airway surface hydration and cystic fibrosis pathogenesis.

Decreased ASL depth has classically been attributed to Na⁺ hyperabsorption as a consequence of absent CFTR [43–46]. Similar to what has recently been reported in CF pig [47] and ferret [48], the cystic fibrosis rat does not exhibit sodium hyperabsorption in either nasal or lower airways. Although amiloride-sensitive sodium transport is not significantly different between wild-type and CFTR⁻/⁻ rats, ASL depth is markedly diminished (Figures 4 and 5). The abrogation of constitutively active CFTR fluid secretion may provide part of the explanation for ASL depletion in CF animals (as opposed normal levels of ASL observed in the CF porcine model) [47]. Our findings therefore suggest that CFTR (rather than ENaC) serves as the dominant regulator of ASL depth in the rat airway in vivo.

It has recently been argued that mucus in cystic fibrosis lungs is excessively viscous due to loss of CFTR dependent bicarbonate secretion, and that the newly formed mucus gel fails to properly expand [49]. We observed markedly increased mucus stores (i.e. cells appear ‘stuffed’ with mucus; Figure 4) in epithelial cells from the proximal nasal septa of CF compared to non-CF mice. Histological findings such as these are compatible with an intrinsic defect in mucus secretion/release [50]. CF pigs develop mucus cell hyperplasia [51] qualitatively similar to that observed in our young CFTR⁻/⁻ animals, and CF mice have also been reported to exhibit a phenotype characterized by measurably increased numbers of mucous cells [52]. Based on findings shown in Figure 4 and Table 1, the rat model should be useful for investigating CFTR-dependent airway mucin synthesis, expansion, and release.

The generation of the first CFTR⁻/⁻ rat using zinc finger nuclease technology suggests a clear path to other CF animal models with specific mutations relevant to therapeutic development, including animals that express F508del or CFTR premature truncations alleles. The advantages of a rat model for CF drug development include robust and multi-organ bioelectric and histological findings, ease of breeding, short gestation, manageable expense, availability of antibodies and other reagents for mechanistic studies, and standard use for pharmacokinetic and drug toxicity analysis.

In summary, the CFTR⁻/⁻ rat exhibits many features of the CF phenotype found in human subjects and CF animal models (summarized in Table 2), including defects in airway mucus production (Figure 4), tracheal development (Table 1), airway surface and periciliary fluid depth (Figure 6), nasal mucus (Figure 4), dentition (Figure 8), and involution of the vas deferens (Figure 7). Bioelectric findings in rat are also informative and demonstrate significantly diminished periciliary fluid without evidence of ENaC hyperactivity. Moreover, unlike the CF ferret or pig, the CFTR⁻/⁻ rat does not present with meconium ileus at birth. Only after weaning do large numbers of animals develop intestinal blockage, which appears similar to the distal intestinal obstruction syndrome observed in children and adults with cystic fibrosis [53]. Complications due to intestinal obstruction can be managed by use of dietary modification (Figure 2). The new CF rat model will provide a very useful resource for longitudinal studies of tissue development, electrophysiology, and other endpoints relevant to disease mechanism in the future.

### Supporting Information

**Figure S1** Analysis of lung tissue from CF rats. (A) Lung histology of wild-type and CFTR⁻/⁻ animals. Magnification bar = 200 μm (n = 7–11 animals/group). (B) Total cell counts and cell differential of BAL in wild-type and CF rats (n = 4 animals/group). (TIF)

**Figure S2** Histology of pancreas and liver from CF rats. H&E stained paraffin sections of (A) pancreas and (B) liver from 22–44 day old wild-type and CFTR⁻/⁻ rats. Magnification bar = 100 μm (n = 3–5 animals/group). (TIF)

**Figure S3** Expanded western blot (see Figure 2). Western indicating absence of CFTR protein from lungs of CFTR⁻/⁻ animals and expression of CFTR in wild-type samples. Arrow - rat CFTR (~150 kDa as previously reported [54]); *indicates likely CFTR degradation product commonly observed in CFTR preparations. This experiment has been repeated three times in separate animals with similar results. (TIF)

---

**Table 2. Summary of phenotypes across numerous CF species.**

<table>
<thead>
<tr>
<th>Condition</th>
<th>Human</th>
<th>Mouse</th>
<th>Pig</th>
<th>Ferret</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>Increased Stored Nasal Mucus</td>
<td>NR</td>
<td>Yes [52]</td>
<td>Yes [51]</td>
<td>NR</td>
<td>Yes</td>
</tr>
<tr>
<td>Airway Surface Hydration</td>
<td>NR</td>
<td>Depleted [55]</td>
<td>Not Depleted [47]</td>
<td>NR</td>
<td>Depleted</td>
</tr>
<tr>
<td>Sodium Hyperabsorption</td>
<td>Yes [41,56], No [57]</td>
<td>Yes [58], No [59]</td>
<td>No [47]</td>
<td>No [48]</td>
<td>No</td>
</tr>
<tr>
<td>Intestinal Obstruction</td>
<td>13–17% MTD, 7–8% DIOS in childhood [60]</td>
<td>0–95% OB at weaning [4]</td>
<td>100% MI [61]</td>
<td>50–100% MI [7]</td>
<td>~70% OB between weaning and 42 DPN</td>
</tr>
<tr>
<td>Vas deferens</td>
<td>~99% CBAVD [35]</td>
<td>Normal</td>
<td>Degenerate or absent vas at birth [29]</td>
<td>Degenerate or absent vas at birth [7]</td>
<td>Vas absent before 42 DPN</td>
</tr>
</tbody>
</table>


*Background strain and/or CFTR genotype dependent.

doi:10.1371/journal.pone.0091253.t002
Characterization of a CFTR-Knockout Rat

Author Contributions
Conceived and designed the experiments: KLT SEB XC DMB SMR EJS MFV. Performed the experiments: KLT SEB JH JW LR AC DJ LPT JF MD MFV. Analyzed the data: KLT SEB KKC GT MD DMB SMR EJS MFV. Contributed reagents/materials/analysis tools: KKC GT. Wrote the paper: KLT SEB XC MD EJS MFV. Coordinated Collaboration: KG. Provided veterinary care and assisted with animal husbandry: JMC.

Acknowledgments
We thank the UAB Comparative Pathology and CMBD Core Laboratories for processing samples. We also thank the UAB Animal Resource Program staff, who have assisted with breeding and rat husbandry. The authors also thank Dr. Trenton Schoeb for his review and analysis of tissue sections.

References